scholarly journals A Randomized Placebo-Controlled Pilot Trial of Omega-3 Fatty Acids and Alpha Lipoic Acid in Alzheimer's Disease

2013 ◽  
Vol 38 (1) ◽  
pp. 111-120 ◽  
Author(s):  
Lynne Shinto ◽  
Joseph Quinn ◽  
Thomas Montine ◽  
Hiroko H. Dodge ◽  
William Woodward ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Fatty Acids ◽  
Lipoic Acid ◽  
Pilot Trial ◽  
Alpha Lipoic Acid ◽  
Omega 3 Fatty Acids ◽  
Omega 3

scholarly journals Omega-3 Fatty Acids in Early Prevention of Inflammatory Neurodegenerative Disease: A Focus on Alzheimer’s Disease

2015 ◽  
Vol 2015 ◽  
pp. 1-13 ◽  
Author(s):  
J. Thomas ◽  
C. J. Thomas ◽  
J. Radcliffe ◽  
C. Itsiopoulos
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Fatty Acids ◽  
Neurodegenerative Disease ◽  
Dietary Intervention ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Early Prevention ◽  
Markers Of Inflammation ◽  
Long Chain

Alzheimer’s disease (AD) is the leading cause of dementia and the most common neurodegenerative disease in the elderly. Furthermore, AD has provided the most positive indication to support the fact that inflammation contributes to neurodegenerative disease. The exact etiology of AD is unknown, but environmental and genetic factors are thought to contribute, such as advancing age, family history, presence of chronic diseases such as cardiovascular disease (CVD) and diabetes, and poor diet and lifestyle. It is hypothesised that early prevention or management of inflammation could delay the onset or reduce the symptoms of AD. Normal physiological changes to the brain with ageing include depletion of long chain omega-3 fatty acids and brains of AD patients have lower docosahexaenoic acid (DHA) levels. DHA supplementation can reduce markers of inflammation. This review specifically focusses on the evidence in humans from epidemiological, dietary intervention, and supplementation studies, which supports the role of long chain omega-3 fatty acids in the prevention or delay of cognitive decline in AD in its early stages. Longer term trials with long chain omega-3 supplementation in early stage AD are warranted. We also highlight the importance of overall quality and composition of the diet to protect against AD and dementia.

scholarly journals Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease

2015 ◽  
Vol 35 (24) ◽  
pp. 9173-9181 ◽  
Author(s):  
B. T. Casali ◽  
A. W. Corona ◽  
M. M. Mariani ◽  
J. C. Karlo ◽  
K. Ghosal ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Fatty Acids ◽  
Mouse Model ◽  
Nuclear Receptor ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Receptor Agonists ◽  
Model Of Alzheimer’S Disease

P3-453: Weight gain by Omega-3 fatty acids in patients with Alzheimer's disease

2006 ◽  
Vol 2 ◽  
pp. S509-S509
Author(s):  
Gerd Faxén Irving ◽  
Yvonne Freund Levi ◽  
Hans Basun ◽  
Anita Garlind ◽  
Maria Eriksdotter Jönhagen ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Fatty Acids ◽  
Weight Gain ◽  
Omega 3 Fatty Acids ◽  
Omega 3
Sign in / Sign up

Export Citation Format

Share Document